Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2578767 | Thérapie | 2015 | 6 Pages |
Abstract
Medical devices (MDs) cover a wide variety of products. They accompany changes in medical practice in step with technology innovations. Innovations in the field of MDs can improve the conditions of use of health technology and/or modify the organisation of care beyond the strict diagnostic or therapeutic benefit for the patients. However, these non purely clinical criteria seem to be only rarely documented or taken into account in the assessment of MDs during reimbursement decisions at national level or for formulary listing by hospitals even though multidimensional models for the assessment of health technologies have been developed that take into account the views of all stakeholders in the healthcare system In this article, after summarising the background concerning the assessment of health technologies in France, a definition of non-clinical criteria for the assessment of MDs is proposed and a decision tree for the assessment of MDs is described. Future lines of approach are proposed as a conclusion.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
Benoît Dervaux, Karine Szwarcensztein, Anne Josseran, participants of round table N°4 of Giens XXX: participants of round table N°4 of Giens XXX:, Alexandre Barna, Cédric Carbonneil, Karine Chevrie, Frédérique Debroucker, Anne Grumblat,